1. A Polymorphism at the Translation Start Site of the Vitamin D Receptor Gene Is Associated with the Response to Anti-Osteoporotic Therapy in Postmenopausal Women from Southern Italy
- Author
-
Walter Filippelli, Michela Grimaldi, Giusy Russomanno, Nicola Maffulli, Valeria D'Argenio, Amelia Filippelli, Giuseppe Toro, Graziamaria Corbi, Valeria Conti, Vittorio Simeon, Nicola Ferrara, Conti, Valeria, Russomanno, Giusy, Corbi, Graziamaria, Toro, Giuseppe, Simeon, Vittorio, Filippelli, Walter, Ferrara, Nicola, Grimaldi, Michela, D'Argenio, Valeria, Maffulli, Nicola, and Filippelli, Amelia
- Subjects
bisphosphonate ,medicine.medical_treatment ,Osteoporosis ,Calcitriol receptor ,lcsh:Chemistry ,Strontium ranelate ,VDR genotype ,lcsh:QH301-705.5 ,Spectroscopy ,pharmacogenetics ,Bone mineral ,Alendronate ,Bone Density Conservation Agents ,vitamin D, post-menopausal, bisphosphonates ,Pharmacogenetic ,General Medicine ,Middle Aged ,Pharmacogenetics ,postmenopausal osteoporosis ,bone mineral density ,rs1544410 ,rs2228570 ,Computer Science Applications ,Postmenopause ,Treatment Outcome ,Italy ,Female ,medicine.drug ,musculoskeletal diseases ,medicine.medical_specialty ,0699 Other Biological Sciences ,Single-nucleotide polymorphism ,Thiophenes ,Polymorphism, Single Nucleotide ,Article ,Catalysis ,Inorganic Chemistry ,Internal medicine ,0399 Other Chemical Sciences ,medicine ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,0604 Genetics ,Chemical Physics ,business.industry ,Organic Chemistry ,Case-control study ,Bisphosphonate ,medicine.disease ,pharmacogenetics, postmenopausal osteoporosis, bisphosphonate, bone mineral density, VDR genotype, rs1544410, rs2228570 ,Endocrinology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Case-Control Studies ,Receptors, Calcitriol ,Postmenopausal osteoporosi ,business - Abstract
The present study investigated the effect of two single nucleotide polymorphisms (SNPs) of the vitamin D receptor (VDR) gene, rs1544410 A/G and rs2228570 C/T, in modulating bone mineral density (BMD) and the response to treatment with bisphosphonates or strontium ranelate in postmenopausal osteoporosis (PMO). Four hundred eighteen postmenopausal women from Southern Italy treated with bisphosphonates or strontium ranelate for three years were enrolled and stratified according to their genotype. Changes in BMD were expressed as the delta t-score (Δt-score). Allelic frequencies for rs1544410 A/GSNP were 11.2% AA, 50.0% GA and 38.8% GG, for rs2228570 C/TSNP were 54.8% CC, 39.5% TC and 5.7% TT. TT carriers showed a lower t-score than TC and CC (both p <, 0.02) genotypes and were more responsive to the therapy when compared to both TC (p <, 0.02) and CC (p <, 0.05) carriers. Specifically, TT carriers receiving alendronate demonstrated a significant improvement of the Δt-score compared to TC and CC (both p <, 0.0001) carriers. After adjustment for confounders, the Δt-score showed evidence of a statistically significant positive association with TT in all treatments considered. Therapy response was independent of rs1544410 A/G SNP, instead, rs2228570 C/TSNP was associated with a better response to antiresorptive treatment, thus suggesting that the therapy for PMO should be personalized.
- Published
- 2015